CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of colorectal cancer.
  
  LEARNING OBJECTIVES

  • Optimize the use of adjuvant chemotherapy for patients with localized colorectal cancer (CRC), considering various clinical and biologic factors such as age, performance status, disease stage, et cetera.
  • Develop a long-term plan to guide the selection and sequencing of therapies for patients diagnosed with metastatic CRC (mCRC), considering biomarker profile, tumor location, prior systemic therapy, symptomatology and personal goals for treatment.
  • Appreciate published research documenting the efficacy of combined BRAF/EGFR inhibition for patients with relapsed/refractory mCRC and a BRAF V600E mutation, and optimally incorporate this therapeutic strategy into practice.
  • Recognize available data with anti-HER2 therapy for HER2-positive mCRC, and consider the current and future roles of various investigational approaches.
  • Evaluate available data with and the FDA approvals of immune checkpoint inhibitor therapies for microsatellite instability-high or mismatch repair-deficient CRC, and optimally select patients for treatment with these agents.
  • Apply available and emerging research to optimize the selection and sequencing of later-line therapeutic options for patients with multiregimen-relapsed mCRC.
  • Recall ongoing trials evaluating novel agents and strategies for CRC, and use this information to appropriately refer patients for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Pashtoon M Kasi, MD, MS
  Director, Colon Cancer Research
  Director, Liquid Biopsy Research
  Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
  Englander Institute for Precision Medicine
  Division of Hematology and Medical Oncology
  NewYork-Presbyterian Hospital/Weill Cornell Medicine
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, BostonGene, Daiichi Sankyo Inc, Delcath Systems Inc, DoMore Diagnostics, Eisai Inc, Exact Sciences Corporation, Foundation Medicine, Illumina, Incyte Corporation, Lilly, Merck Sharp & Dohme LLC, Natera Inc, NeoGenomics, QED Therapeutics, SAGA Diagnostics AB, Seagen Inc, Servier Pharmaceuticals LLC, Taiho Oncology Inc, Tempus; Scientific Advisory Board Member: Elicio Therapeutics; Stock Options/Ownership — Public Company: Elicio Therapeutics (Angion Biomedica Corp).
  
  Wells A Messersmith, MD
  Chief Medical Officer, Oncology Services
  Professor and Head, Division of Medical Oncology
  University of Colorado Cancer Center
  Aurora, Colorado
  
  Consulting Agreements: Cardiff Oncology, Istari Oncology; Contracted Research: ALX Oncology, AStar EDDC, BeiGene Ltd, CanBas Co Ltd, Exelixis Inc, Fate Therapeutics, Pfizer Inc, PureTech Health, Mirati Therapeutics Inc, Rascal Therapeutics; Data and Safety Monitoring Board/Committee: Amgen Inc, QED Therapeutics, Zymeworks Inc; Unpaid Advisory Board: Pfizer Inc, Takeda Pharmaceuticals USA Inc; Nonrelevant Financial Relationship: Criterium.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from Merck, Natera Inc, Seagen Inc, and Taiho Oncology Inc.
  
  Release date: May 2023
  Expiration date: May 2024